Get started
Author

Jeremy Cole

Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial
2023 · W Timothy Garvey, Juan P Frias, et al. · The Lancet · 866
PDF
Dupilumab for COPD with Type 2 Inflammation Indicated by Eosinophil Counts
2023 · Surya P. Bhatt, Klaus F. Rabe, et al. · New England Journal of Medicine · 566
Onset of effect and impact on health-related quality of life, exacerbation rate, lung function, and nasal polyposis symptoms for patients with severe eosinophilic asthma treated with benralizumab (ANDHI): a randomised, controlled, phase 3b trial
2020 · Tim W Harrison, Pascal Chanez, et al. · The Lancet Respiratory Medicine · 186
Long-term safety and efficacy of tezepelumab in people with severe, uncontrolled asthma (DESTINATION): a randomised, placebo-controlled extension study
2023 · Andrew Menzies-Gow, Michael E Wechsler, et al. · The Lancet Respiratory Medicine · 172
PDF
Efficacy and safety of tezepelumab versus placebo in adults with moderate to very severe chronic obstructive pulmonary disease (COURSE): a randomised, placebo-controlled, phase 2a trial
2024 · Dave Singh, Christopher E Brightling, et al. · The Lancet Respiratory Medicine · 89
CYT 003, a TLR 9 agonist, in persistent allergic asthma – a randomized placebo‐controlled Phase 2b study
2015 · T. B. Casale, J. Cole, et al. · Allergy · 69
Dupilumab leads to better-controlled asthma and quality of life in children: the VOYAGE study
2023 · Alessandro G. Fiocchi, Wanda Phipatanakul, et al. · European Respiratory Journal · 48
Benralizumab does not impair antibody response to seasonal influenza vaccination in adolescent and young adult patients with moderate to severe asthma: results from the Phase IIIb ALIZE trial
2018 · Pamela L Zeitlin, Mila Leong, et al. · Journal of Asthma and Allergy · 48
PDF
Inhaled fluticasone furoate/vilanterol does not affect hypothalamic‐pituitary‐adrenal axis function in adolescent and adult asthma: randomised, double‐blind, placebo‐controlled study
2013 · Ann Allen, Isabelle Schenkenberger, et al. · The Clinical Respiratory Journal · 44
PDF
Severe Asthma Standard-of-Care Background Medication Reduction With Benralizumab: ANDHI in Practice Substudy
2023 · Renaud Louis, Tim W. Harrison, et al. · The Journal of Allergy and Clinical Immunology In Practice · 28
PDF
Safety and efficacy of astegolimab for COPD with frequent exacerbations regardless of baseline blood eosinophil counts (ALIENTO and ARNASA): randomised, double-blind, placebo-controlled, phase 2b and 3 trials
2026 · Alberto Papi, Neil J Greening, et al. · The Lancet · 27
Single-Use Autoinjector Functionality And Reliability For At-Home Administration Of Benralizumab For Patients With Severe Asthma: GRECO Trial Results
2019 · Gary T. Ferguson, Jeremy Cole, et al. · Journal of Asthma and Allergy · 23
PDF
Safety and Efficacy Of ARRY-502, a Potent, Selective, Oral CRTh2 Antagonist, In Patients With Mild To Moderate Th2-Driven Asthma
2014 · Sally E. Wenzel, Robert Hopkins, et al. · Journal of Allergy and Clinical Immunology · 14
PDF
Effect of Tezepelumab on the Humoral Immune Response to Seasonal Quadrivalent Influenza Vaccination in Patients with Moderate to Severe Asthma: The Phase 3b VECTOR Study
2023 · Jeremy Cole, Iwona Cąpała-Szczurko, et al. · Pulmonary Therapy · 8
PDF
Dupilumab efficacy in high sleep disturbance management among patients with type 2 asthma
2023 · Jorge F. Maspero, Shirin Shafazand, et al. · Respiratory Medicine · 6
PDF
Single-Use Autoinjector Functionality and Reliability for At-Home Benralizumab Administration: GRECO Trial Results
2019 · Peter Barker, Gary T. Ferguson, et al. · Journal of Allergy and Clinical Immunology · 6
PDF
Dupilumab improves asthma control and quality of life in children with uncontrolled persistent asthma
2021 · Alessandro Fiocchi, Wanda Phipatanakul, et al. · European Respiratory Journal · 2
No Effect of Benralizumab Treatment on Antibody Response to Seasonal Influenza Vaccination in Adolescent and Young Adult Patients With Moderate to Severe Asthma: Results From the Phase IIIb ALIZE Trial
2018 · Pamela L. Zeitlin, Mila Leong, et al. · Journal of Allergy and Clinical Immunology · 2
Efficacy and Safety of Dupilumab for Copd With Type 2 Inflammation
2023 · SURYA P BHATT, KLAUS F RABE, et al. · CHEST Journal · 1
P38 Dupilumab Improves Quality of Life in Caregivers of Children with Uncontrolled Moderate-to-Severe Asthma: Liberty Asthma Voyage Study
2022 · AG. Fiocchi, W. Phipatanakul, et al. · Value in Health · 1
Dupilumab Improves Asthma Control, and Allergic Rhinitis-Related Health-Related Quality of Life in Children With Uncontrolled Persistent Asthma With Comorbid Allergic Rhinitis
2022 · Alessandro Fiocchi, Wanda Phipatanakul, et al. · Journal of Allergy and Clinical Immunology · 1
Late Breaking Abstract - A single dose of zumilokibart (APG777) durably suppresses FeNO through 32 weeks in patients with mild-to-moderate asthma
2026 · Mario Castro, Jeremy Cole, et al. · European Respiratory Journal
Effect of Dupilumab on Sleep Disturbance in Patients With Uncontrolled Moderate-to-Severe Asthma, Type 2 Inflammation, and Nocturnal Awakenings: The MORPHEO Randomized Controlled Trial
2026 · Jorge F Maspero, Anil Gupta, et al. · Journal of Investigational Allergology and Clinical Immunology
B32-49 Early and Sustained Suppression of FeNo With a Single Dose of Zumilokibart (APG777), a Novel Half-Life-Extended Anti-Il-13 Antibody, in Patients With Mild-to-Moderate Asthma
2026 · D Singh, J Cole, et al. · American Journal of Respiratory and Critical Care Medicine
Tezepelumab Did Not Appear to Affect the Humoral Immune Response to Seasonal Quadrivalent Influenza Vaccination in Patients With Moderate-to-severe Asthma (vector)
2023 · JEREMY COLE, IWONA CAPALA-SZCZURKO, et al. · CHEST Journal
PDF
Works count: 28
Citation count: 2,207
H-index: 13
I10-index: 13
Year
Topic
Type